Table 2.
Results by PAH functional class at initiation of therapy
| Treatment | Discounted costs ($) | Discounted QALYs | Incremental cost per QALY compared with sildenafil |
|---|---|---|---|
| Functional class II | |||
| Sildenafil | $146,254 | 4.663 | |
| Tadalafil | $153,245 | 4.002 | Dominated by sildenafil |
| Supportive care | $155,156 | 3.218 | Dominated by sildenafil |
| Ambrisentan 5 mg | $377,187 | 4.634 | Dominated by sildenafil |
| Ambrisentan 10 mg | $377,523 | 4.217 | Dominated by sildenafil |
| Riociguat | $388,491 | 4.244 | Dominated by sildenafil |
| Bosentan | $406,282 | 3.904 | Dominated by sildenafil |
| Functional class III | |||
| Sildenafil | $181,119 | 3.284 | |
| Tadalafil | $200,584 | 3.013 | Dominated by sildenafil |
| Supportive care | $204,285 | 2.687 | Dominated by sildenafil |
| Ambrisentan 5 mg | $351,573 | 3.180 | Dominated by sildenafil |
| Ambrisentan 10 mg | $376,884 | 3.043 | Dominated by sildenafil |
| Riociguat | $383,582 | 3.045 | Dominated by sildenafil |
| Bosentan | $412,979 | 2.960 | Dominated by sildenafil |
All costs are expressed in Canadian dollars
Dominated more costly and fewer QALYs, QALY quality-adjusted life-year, PAH pulmonary arterial hypertension